Pulmonary Pharmacology & Therapeutics

Papers
(The TQCC of Pulmonary Pharmacology & Therapeutics is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-07-01 to 2026-07-01.)
ArticleCitations
Celebrating the appointment of Mario Cazzola as Honorary Editor of Pulmonary Pharmacology & Therapeutics41
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study39
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies31
Echocardiographic effects of dupilumab in patients with severe type 2 asthma28
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)25
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d25
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients22
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function20
Editorial Board20
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation19
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens19
Editorial Board18
Editorial Board18
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets16
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential15
Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment15
Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis14
FTO regulates the proliferation and apoptosis of pulmonary artery smooth muscle cells through m6A demethylation modification14
Triple inhaled therapy in asthma: Beliefs, behaviours and doubts13
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study13
Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea13
Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma13
Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score12
Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis12
Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler12
Ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced acute lung injury12
Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant12
Unveiling the protective role of sevoflurane in video-assisted thoracoscopic surgery associated-acute lung injury: Inhibition of ferroptosis12
Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials11
Editorial Board11
The era of multiple biologics: Is combination and switching an option in the management of severe asthma?11
Editorial Board11
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis11
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study11
Ensifentrine approval: A milestone in the treatment of COPD11
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea10
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics10
Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients10
Editorial Board10
Pulmonary safety of Staccato alprazolam in healthy participants and participants with mild asthma: Phase 1, randomized, double-blind, placebo-controlled trial10
The wonders of stem cells therapeutic application towards chronic obstructive pulmonary disease9
Editorial Board9
Drug-drug interactions in vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor-ivacaftor9
0.11128902435303